• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Morphosys Ag ADR (NQ: MOR )

    18.96 UNCHANGED
    Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 18.96
    Bid (Size) 17.81 (3)
    Ask (Size) 19.00 (10)
    Prev. Close 18.96
    Today's Range 18.96 - 18.96
    52wk Range 4.185 - 19.50
    Shares Outstanding 32,890,046
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    3 Global Stocks to Buy to Escape the Volatility on Wall Street
    Discover three top global stocks as a smart hedge against Wall Street volatility, offering diversification and resilience in uncertain times. 
    Via InvestorPlace

    Performance

    YTD
    +96.68%
    +96.68%
    1 Month
    +2.99%
    +2.99%
    3 Month
    +2.27%
    +2.27%
    6 Month
    +7.60%
    +7.60%
    1 Year
    +140.00%
    +140.00%

    More News

    Read More
    MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
    From MorphoSys AG
    Via Business Wire
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DM, SHCR, MOR, ALE on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    MorphoSys: Q4 Earnings Insights
    Via Benzinga
    Earnings Outlook For MorphoSys
    Via Benzinga
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, MOR, BEST, MGOL on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
    From MorphoSys AG
    Via Business Wire
    Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
    Via ACCESSWIRE
    Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    MOR Stock Earnings: MorphoSys Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    MorphoSys AG Reports First Quarter 2024 Financial Results
    From MorphoSys AG
    Via Business Wire
    MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
    Via Benzinga
    Exposures Product Safety
    MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
    Via ACCESSWIRE
    Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
    Via Benzinga
    MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
    From MorphoSys AG
    Via Business Wire
    MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
    Via ACCESSWIRE
    MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
    Via ACCESSWIRE
    MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    From MorphoSys AG
    Via Business Wire
    Earnings Scheduled For March 13, 2024
    Via Benzinga
    5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
    Via Talk Markets
    3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
    Via InvestorPlace
    Exit Now! 3 Biotech Stocks to Sell in February 2024
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.